Market News & Trends
Enable Injections & Serina Therapeutics Announce Agreement to Develop SER-252 in Combination With enFuse for Advanced Parkinson’s Disease
Enable Injections, Inc. and Serina Therapeutics recently announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson’s…
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Medigene AG recently presented the company’s proprietary T cell receptor (TCR) discovery process to obtain optimal affinity 3S (sensitive, specific and safe) TCRs at the…
PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….
Roquette Unlocks the Power of Flexibility With Launch of New Flex Softgel Capsule Shell System
Roquette recently announced the launch of its new LYCAGEL Flex hydroxypropyl pea starch premix for nutraceutical and pharmaceutical softgel capsules. Built on Roquette’s market-first LYCAGEL pea…
CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell…
Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of….
ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques
ElevateBio is building a robust portfolio of patents protecting its novel technologies while the Company scales as the world’s first integrated genetic medicine foundry….
PTC Therapeutics Announces FDA Acceptance & Priority Review of BLA
PTC Therapeutics, Inc. recently announced the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza (eladocagene exuparvovec), a gene therapy for the…
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration With Vividion Therapeutics
Tavros Therapeutics, Inc. recently announced it has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary…
CENTOGENE & Evotec Discover Promising New Molecule to Treat Gaucher Disease
Centogene N.V. recently announced the discovery of a new small molecule together with Evotec SE. The new molecule has the potential to treat patients with…
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo Pharma, Inc. recently announced its planned attendance at a hybrid public meeting on June 27, 2024, hosted by the US FDA in partnership with…
AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
Recursion recently announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVIDIA…
AC Immune & Takeda Sign Exclusive Option & License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression….
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic
Lycia will use proceeds from financing to progress its lead programs into the clinic for autoimmune and inflammatory diseases….
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
IMUNON, Inc. recently announced DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for its Phase 1 study with…
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy & Related Conditions
Beacon Biosignals recently announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard’s drug development expertise with Beacon’s neurophysiological platform to develop a better…
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
Valneva SE recently reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day…
Data From First Human Study Demonstrate Excellent Performance of Zerion Pharma’s Dispersome Technology
Zerion Pharma A/S recently announced positive results from the first human clinical study of a Dispersome formulation of the drug Ivacaftor, a pharmaceutical used to…
Genespire Presents Positive Preclinical Proof of Concept Data
Genespire recently presented positive preclinical data at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) currently taking place in…
